Biogen continued as a buy at UBS despite Aduhelm agreement change with Eisai
koto_feja/E+ via Getty Images


UBS is maintaining its buy rating on Biogen (NASDAQ:BIIB
+2.2%) despite Tuesday's announcement that the biotech is taking sole commercial rights to Alzheimer's treatment Aduhelm (aducanumab) from partner Eisai (OTCPK:ESALY
-0.1%).
The firm has a $269 price target (~36% upside based on Tuesday's close).

Analyst Colin Bristow said that the Street already has a bearish outlook on Aduhelm, so the Eisai (OTCPK:ESALF) announcement shouldn't have much of an impact.
Bristow cautioned that for his buy thesis to work, one of three things must occur: a less restrictive coverage determination on Aduhelm from the Centers for Medicare and Medicaid Services; positive phase 3 data on Alzheimer's candidate lecanemab; or business development that leads revenue/earnings and/or pipeline improvements.
Read why Seeking Alpha contributor says that Biogen (BIIB
+2.2%) is a buy.